Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFD-29 (minocycline) for inflammatory lesions of rosacea
2021-005382-40Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline hydrochloride modified release (DFD-29) in rosacea (3 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Safety and tolerability. Started Mar 2022; status: completed.
02
Drugs
minocycline hydrochloride modified release (DFD-29)
03
Conditions
rosacea
Beyond the preview
Go deeper on 2021-005382-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005382-40.